{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ahimbisibwe G"],"funding":["University College London Hospitals NHS Foundation Trust","Cancer Research UK","Medical Research Council","NIHR University College London Hospitals Biomedical Research Centre","The Francis Crick Institute","NIHR Imperial Biomedical Research Centre","Imperial College Healthcare NHS Trust","Wellcome Trust","UK Research and Innovation"],"pagination":["106598"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7618389"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["91(3)"],"pubmed_abstract":["<h4>Background</h4>In 2021, the rapid rollout of two doses of SARS-CoV-2 vaccines reduced COVID-19 severity and mortality. However, further vaccine doses as a prime-boost schedule were limited, and lifting of public health restrictions by late 2021 frequently led to infection, rather than vaccine, as a third exposure.<h4>Objective</h4>To compare how the third exposure through mRNA booster or SARS-CoV-2 infection shapes humoral and cellular immunity following two vaccine doses.<h4>Methods</h4>We compared immune responses after the third exposure in healthy adults enrolled in the UCLH-Crick Legacy cohort study (NCT04750356) between those receiving ancestral spike-encoded mRNA booster (vaccine immunity, n = 38) or COVID-19 infection (hybrid immunity, n = 13) following two vaccine doses. Immun"],"journal":["The Journal of infection"],"pubmed_title":["Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses."],"pmcid":["PMC7618389"],"funding_grant_id":["MR/W005611/1","CC2230","CC2166","CC2060","226817","CC2041","CC1283","222574","MR/X006751/1","CC0102","CC1114","MR/Y004205/1","CC2112"],"pubmed_authors":["Penn R","Swanton C","Carr EJ","Levi D","Ahimbisibwe G","Gahir J","Miah M","Harvey R","Wilkinson RJ","Bawumia P","Williams B","Bauer DL","Riddell A","Legacy Investigators","Kelly G","Townsley H","Daley O","Bazire J","Kjar S","Stevenson-Leggett P","Smith C","Gamblin S","Sanderson T","Fowler AS","Hobson P","Wilkinson KA","Dowgier G","Ambrose K","Hobbs A","Greenwood D","Libri V","Gandhi S","Wall EC","Miranda M","O'Reilly N","Warchal S","Strange A","Chaloner C"],"additional_accession":[]},"is_claimable":false,"name":"Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.","description":"<h4>Background</h4>In 2021, the rapid rollout of two doses of SARS-CoV-2 vaccines reduced COVID-19 severity and mortality. However, further vaccine doses as a prime-boost schedule were limited, and lifting of public health restrictions by late 2021 frequently led to infection, rather than vaccine, as a third exposure.<h4>Objective</h4>To compare how the third exposure through mRNA booster or SARS-CoV-2 infection shapes humoral and cellular immunity following two vaccine doses.<h4>Methods</h4>We compared immune responses after the third exposure in healthy adults enrolled in the UCLH-Crick Legacy cohort study (NCT04750356) between those receiving ancestral spike-encoded mRNA booster (vaccine immunity, n = 38) or COVID-19 infection (hybrid immunity, n = 13) following two vaccine doses. Immun","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-05T18:33:12.113Z","creation":"2026-05-20T03:12:12.828Z"},"accession":"S-EPMC7618389","cross_references":{"pubmed":["40848990"],"doi":["10.1016/j.jinf.2025.106598"]}}